BIOTECH ASSISTANT / FIELD NOTES

Medicilon reports nine-month revenue growth of 44.13%

Regulatory / securities filing · 美迪西 / 巨潮资讯 CNinfo

Source published: 2026-10-30 · Event / reporting date: 2026-09-30

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Medicilon reported consolidated revenue of RMB1.215 billion, up 44.13%, and attributable net income of RMB92.0 million for the nine months ended September 30, 2026. The company returned to profit. Its report does not present a conventional positive-base growth rate for attributable earnings. The quarterly filing is unaudited and covers the year-to-date period.

Why it may matter

The preclinical outsourcing recovery merits attention, while margins, cash collection, and order durability will help test whether it can continue.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

China-listed CRO/CDMO

Follow the evidence

Companies mentionedMedicilon ↗

Explore field companies →Explore literature →

Related updates

2026-11-06Bio-S Pharmaceutical

Bio-S and XtalPi unveil joint drug-discovery platform in Shanghai

Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.

Companies mentionedXtalPi ↗

China-listed CRO/CDMO Ask AI ↗

2026-11-02Fresenius

Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates

Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.

Companies mentionedWuXi Biologics ↗

China-listed CRO/CDMO Ask AI ↗

2026-10-30百奥赛图 / 巨潮资讯 CNinfo

Biocytogen reports nine-month revenue growth of 49.09%

Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.

Companies mentionedBiocytogen ↗

China-listed CRO/CDMO Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗